Clinical trial · Observational
Non-interventional Study on Patients With Atrial Fibrillation and Cancer
Multicenter, Non-interventional Study on Patients With Atrial Fibrillation (AF) and Cancer (Diagnosed Within the Last 3 Years Prior to Enrolment)
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
AF and cancer frequently coexist. Since these patients are usually excluded from randomized trials, information on their management and outcome is scarce. Occurrence of relevant clinical events, such as ischemic and hemorrhagic and all-cause mortality and cardiovascular (CV) mortality occurring in patients treated or not with antithrombotic agents needs to be clarified. A prospective observational registry collecting information, in a real world setting, on the clinical profile of patients with these clinical conditions and on the use of antithrombotic drugs in patients with AF and cancer could improve our knowledge on the management of these high risk patients.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Atrial Fibrillation | — | UNRESOLVED | — |
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (2)
- measure
- Patients with AF and cancer treated with oral anticoagulant therapy and with other antithrombotic therapy
- timeFrame
- Baseline
- description
- Number of patients with AF and cancer treated with oral anticoagulant therapy and with other antithrombotic therapy
- measure
- Patients with AF and cancer treated with oral anticoagulant therapy and with other antithrombotic therapy
- timeFrame
- 12 Months
- description
- Number of patients with AF and cancer treated with oral anticoagulant therapy and with other antithrombotic therapy
Secondary outcomes (19)
- measure
- Patients treated with oral anticoagulant therapy, other antithrombotic therapy or not treated experiencing all cause stroke
- timeFrame
- Baseline and 12 months
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Both sexes * Age \>18 years * Patient with diagnosed AF (any type of AF, electrocardiographically documented within 1 year prior to enrolment) * Patient with a documented cancer (diagnosed within the last 3 years prior to enrolment into this registry), including melanoma but not other basal-cell or squamous-cell carcinoma of the skin. The diagnosis/history of cancer must be objectively documented. * Written informed consent (IC) for participation in the study * Patient not simultaneously participating in any interventional study. Exclusion Criteria: \-
References
Publications (1)
- DERIVEDGulizia MM, Turazza FM, Ameri P, Alings M, Collins R, De Luca L, Di Nisio M, Lucci D, Gabrielli D, Janssens S, Parrini I, Pinto FJ, Zamorano J, Colivicchi F; BLITZ-AF Cancer Investigators. Characteristics and Management of Patients With Cancer and Atrial Fibrillation: The BLITZ-AF Cancer Registry. JACC Adv. 2024 May 24;3(7):100991. doi: 10.1016/j.jacadv.2024.100991. eCollection 2024 Jul. PMID 39130025